Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive immunotherapy for EBV-associated malignancies.

Stephen Gottschalk1, Helen E Heslop, Cliona M Rooney

  • 1Center for Cell and Gene Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA. smg@bcm.tmc.edu

Leukemia & Lymphoma
|December 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026
Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026
Same author

Macrophages as gatekeepers of glioma progression.

Molecular therapy. Oncology·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Introduction to a review series on hemophagocytic lymphohistiocytosis.

Blood·2026

Epstein-Barr virus (EBV) infection links to cancers like lymphoma and nasopharyngeal carcinoma. EBV-specific T cells show promise for treating EBV-lymphoproliferative disease, but face challenges in other EBV-associated cancers.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Latent Epstein-Barr virus (EBV) infection is linked to various malignancies, including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma (NPC), and lymphoproliferative disease (LPD).
  • EBV proteins are targets for adoptive immunotherapy using antigen-specific cytotoxic T cells (CTL).
  • EBV-specific CTL have demonstrated success in preventing and treating EBV-LPD post hematopoietic stem cell transplantation (HSCT).

Purpose of the Study:

  • To evaluate the efficacy of EBV-specific CTL in treating EBV-associated malignancies.
  • To understand the limitations and immune evasion strategies affecting CTL effectiveness in cancers beyond EBV-LPD post HSCT.
  • To explore novel strategies for enhancing CTL potency against EBV-driven tumors.

Main Methods:

Related Experiment Videos

  • Review of clinical experience with EBV-specific CTL in treating EBV-associated malignancies.
  • Analysis of immune evasion mechanisms employed by tumor cells, such as downregulation of EBV proteins and cytokine secretion.
  • Investigation of advanced therapeutic approaches, including targeting subdominant EBV antigens and genetic modification of CTL.

Main Results:

  • Clinical data for EBV-specific CTL in Hodgkin's disease and NPC are limited.
  • EBV-specific CTL show reduced efficacy in treating Hodgkin's disease and NPC compared to EBV-LPD post HSCT.
  • Tumor immune evasion strategies, including reduced viral protein expression and inhibitory cytokine release, likely contribute to decreased CTL effectiveness.

Conclusions:

  • EBV-specific CTL therapy is effective for EBV-LPD post HSCT but shows limited success in other EBV-associated cancers.
  • Immune evasion by tumor cells presents a significant barrier to effective CTL immunotherapy.
  • Strategies such as targeting alternative EBV antigens and enhancing CTL functionality are crucial for improving treatment outcomes in EBV-driven malignancies.